Question 1

Am I eligible to participate in this trial based on my vaccination history?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Immunogenicity and Safety Study of Heterologous Booster Vaccination of a SARS-CoV-2 Recombinant Protein Nanoparticle Vaccine(GBP510) Adjuvanted with AS03 in Adults Aged 18 Years and Older clinical trial (NCT05501522). Contact the study team or your healthcare provider for specific answers.

Question 2

What are the potential side effects of the GBP510 vaccine compared to the placebo?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Immunogenicity and Safety Study of Heterologous Booster Vaccination of a SARS-CoV-2 Recombinant Protein Nanoparticle Vaccine(GBP510) Adjuvanted with AS03 in Adults Aged 18 Years and Older clinical trial (NCT05501522). Contact the study team or your healthcare provider for specific answers.

Question 3

How often will I need to come in for visits during the study?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Immunogenicity and Safety Study of Heterologous Booster Vaccination of a SARS-CoV-2 Recombinant Protein Nanoparticle Vaccine(GBP510) Adjuvanted with AS03 in Adults Aged 18 Years and Older clinical trial (NCT05501522). Contact the study team or your healthcare provider for specific answers.

Question 4

What should I do if I experience any side effects after receiving the vaccine?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Immunogenicity and Safety Study of Heterologous Booster Vaccination of a SARS-CoV-2 Recombinant Protein Nanoparticle Vaccine(GBP510) Adjuvanted with AS03 in Adults Aged 18 Years and Older clinical trial (NCT05501522). Contact the study team or your healthcare provider for specific answers.

Question 5

Will participating in this trial affect my ability to receive other vaccines?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Immunogenicity and Safety Study of Heterologous Booster Vaccination of a SARS-CoV-2 Recombinant Protein Nanoparticle Vaccine(GBP510) Adjuvanted with AS03 in Adults Aged 18 Years and Older clinical trial (NCT05501522). Contact the study team or your healthcare provider for specific answers.

Question 6

How will the results of this trial impact future COVID-19 vaccination recommendations?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Immunogenicity and Safety Study of Heterologous Booster Vaccination of a SARS-CoV-2 Recombinant Protein Nanoparticle Vaccine(GBP510) Adjuvanted with AS03 in Adults Aged 18 Years and Older clinical trial (NCT05501522). Contact the study team or your healthcare provider for specific answers.

What this study is about